DAWN Insider Trading Activity and SEC Form 4 Filings
DAWN insider trading summary
Over the past 12 months, insiders at Day One Biopharmaceuticals, Inc. (DAWN) reported 9 sales worth $673K by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $673K.
Latest DAWN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 17, 2026 | Jeremy Bender | Chief Executive Officer | Sell | $179K (15,459 @ $11.60) |
| Feb 17, 2026 | Adam Dubow | Gen Counsel & Secretary | Sell | $74K (6,395 @ $11.60) |
| Feb 17, 2026 | Michael Vasconcelles | Head of Research and Dev. | Sell | $32K (2,728 @ $11.60) |
| Feb 17, 2026 | Charles N York II | COO and CFO | Sell | $70K (6,065 @ $11.60) |
| Feb 17, 2026 | Lauren Merendino | Chief Commercial Officer | Sell | $67K (5,814 @ $11.60) |
| Nov 17, 2025 | Jeremy Bender | Chief Executive Officer | Sell | $142K (15,894 @ $8.91) |
| Nov 17, 2025 | Adam Dubow | Gen Counsel & Secretary | Sell | $39K (4,319 @ $8.91) |
| Nov 17, 2025 | Charles N York II | COO and CFO | Sell | $36K (4,062 @ $8.91) |
| Nov 17, 2025 | Lauren Merendino | Chief Commercial Officer | Sell | $33K (3,726 @ $8.91) |
| Aug 18, 2025 | Adam Dubow | Gen Counsel & Secretary | Sell | $30K (4,365 @ $6.77) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.